Advancing molecular modeling and reverse vaccinology in broad-spectrum yellow fever virus vaccine development.
Yellow Fever Vaccine
/ immunology
Yellow fever virus
/ immunology
Humans
Yellow Fever
/ prevention & control
Epitopes, T-Lymphocyte
/ immunology
Epitopes, B-Lymphocyte
/ immunology
Vaccinology
/ methods
Models, Molecular
Vaccine Development
Molecular Dynamics Simulation
T-Lymphocytes, Cytotoxic
/ immunology
B-lymphocyte
Cytotoxic T-lymphocyte
Helper T-lymphocyte
Immunoinformatic
Multi-epitope vaccine
Yellow fever
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 05 2024
12 05 2024
Historique:
received:
31
10
2023
accepted:
25
04
2024
medline:
13
5
2024
pubmed:
13
5
2024
entrez:
12
5
2024
Statut:
epublish
Résumé
Yellow fever outbreaks are prevalent, particularly in endemic regions. Given the lack of an established treatment for this disease, significant attention has been directed toward managing this arbovirus. In response, we developed a multiepitope vaccine designed to elicit an immune response, utilizing advanced immunoinformatic and molecular modeling techniques. To achieve this, we predicted B- and T-cell epitopes using the sequences from all structural (E, prM, and C) and nonstructural proteins of 196 YFV strains. Through comprehensive analysis, we identified 10 cytotoxic T-lymphocyte (CTL) and 5T-helper (Th) epitopes that exhibited overlap with B-lymphocyte epitopes. These epitopes were further evaluated for their affinity to a wide range of human leukocyte antigen system alleles and were rigorously tested for antigenicity, immunogenicity, allergenicity, toxicity, and conservation. These epitopes were linked to an adjuvant (
Identifiants
pubmed: 38735993
doi: 10.1038/s41598-024-60680-9
pii: 10.1038/s41598-024-60680-9
doi:
Substances chimiques
Yellow Fever Vaccine
0
Epitopes, T-Lymphocyte
0
Epitopes, B-Lymphocyte
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
10842Informations de copyright
© 2024. The Author(s).
Références
Mutebi, J.-P., Wang, H., Li, L., Bryant, J. E. & Barrett, A. D. Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. J. Virol. 75(15), 6999–7008 (2001).
pubmed: 11435580
pmcid: 114428
doi: 10.1128/JVI.75.15.6999-7008.2001
Wang, E. et al. Genetic variation in yellow fever virus: duplication in the 3’ noncoding region of strains from Africa. Virology 225(2), 274–281 (1996).
pubmed: 8918913
doi: 10.1006/viro.1996.0601
Strode, G. K. Yellow Fever (McGraw-Hill, 1951).
Figueiredo, L. T. M. Febres hemorrágicas por vírus no Brasil. Revista da Sociedade Brasileira de Medicina Tropical 39, 203–210 (2006).
pubmed: 16699651
doi: 10.1590/S0037-86822006000200014
da Vasconcelos, P. F. C. Febre amarela: reflexões sobre a doença, as perspectivas para o século XXI e o risco da reurbanização. Revista Brasileira de Epidemiologia 5, 244–258 (2002).
doi: 10.1590/S1415-790X2002000300004
Vellozzi, C. et al. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: Eleven United States cases, 1996–2004. Am. J. Trop. Med. Hyg. 75(2), 333–336 (2006).
pubmed: 16896144
doi: 10.4269/ajtmh.2006.75.333
De Nishioka, A. S., Nunes-Ara£jo, F., Pires, W. P., Silva, F. A. & Costa, H. L. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop. Med. Int. Health 3(1), 29–33 (1998).
pubmed: 9484965
doi: 10.1046/j.1365-3156.1998.00164.x
Gotuzzo, E., Yactayo, S. & Córdova, E. Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years. Am. J. Trop. Med. Hyg. 89(3), 434 (2013).
pubmed: 24006295
pmcid: 3771278
doi: 10.4269/ajtmh.13-0264
Khromava, A. Y. et al. Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23(25), 3256–3263 (2005).
pubmed: 15837230
doi: 10.1016/j.vaccine.2005.01.089
Lindsey, N. P. et al. Adverse event reports following yellow fever vaccination. Vaccine 26(48), 6077–6082 (2008).
pubmed: 18809449
doi: 10.1016/j.vaccine.2008.09.009
Organization WH, others. Vaccines and vaccination against yellow fever: WHO position paper—June 2013. Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire 2013;88(27):269–283.
Rafferty, E., Duclos, P., Yactayo, S. & Schuster, M. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: A systematic review. Vaccine 31(49), 5798–5805 (2013).
pubmed: 24079979
doi: 10.1016/j.vaccine.2013.09.030
Domingo, C., Charrel, R. N., Schmidt-Chanasit, J., Zeller, H. & Reusken, C. Yellow fever in the diagnostics laboratory. Emerg. Microbes Infect. 7(1), 1–15 (2018).
doi: 10.1038/s41426-018-0128-8
da Vasconcelos, P. F. C. et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: A report of two cases. Lancet 358, 91–97 (2001).
pubmed: 11463409
doi: 10.1016/S0140-6736(01)05326-0
Lawrence, G. L., Burgess, M. A. & Kass, R. B. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun. Dis. Intell. Q. Rep. 28(2), 244–248 (2004).
pubmed: 15460963
Biscayart, C. et al. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina. Vaccine 32(11), 1266–1272 (2014).
pubmed: 24456625
doi: 10.1016/j.vaccine.2014.01.015
Chan, R. C. et al. Hepatitis and death following vaccination with 17D–204 yellow fever vaccine. Lancet 358(9276), 121–122 (2001).
pubmed: 11463415
doi: 10.1016/S0140-6736(01)05341-7
Reinhardt, B., Jaspert, R., Niedrig, M., Kostner, C. & L’age-Stehr, J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection. J. Med. Virol.gy 56(2), 159–167 (1998).
doi: 10.1002/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B
Jennings, A. et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis. 169(3), 512–518 (1994).
pubmed: 7908925
doi: 10.1093/infdis/169.3.512
de Oliveira Campos, D. M. et al. Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants. Comput. Biol. Chem. 101, 107754 (2022).
doi: 10.1016/j.compbiolchem.2022.107754
Dorosti, H. et al. Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine. J. Biomol. Struct. Dyn. 37, 3524–3535 (2019).
pubmed: 30634893
doi: 10.1080/07391102.2018.1519460
Ul-Rahman, A. & Shabbir, M. A. B. In silico analysis for development of epitopes-based peptide vaccine against Alkhurma hemorrhagic fever virus. J. Biomol. Struct. Dyn. 38(10), 3110–3122 (2020).
pubmed: 31370756
doi: 10.1080/07391102.2019.1651673
Murphy, D., Reche, P. & Flower, D. R. Selection-based design of in silico dengue epitope ensemble vaccines. Chem. Biol. Drug Des. 93(1), 21–28 (2019).
pubmed: 29931821
doi: 10.1111/cbdd.13357
Anwar, S., Mourosi, J. T., Khan, M. F. & Hosen, M. J. Prediction of epitope-based peptide vaccine against the chikungunya virus by immuno-informatics approach. Curr. Pharmaceut. Biotechnol. 21(4), 325–340 (2020).
doi: 10.2174/1389201020666191112161743
Silva, M. K. et al. Identification of promiscuous T cell epitopes on Mayaro virus structural proteins using immunoinformatics, molecular modeling, and QM: MM approaches. Infect. Genetics Evol. 91, 104826 (2021).
doi: 10.1016/j.meegid.2021.104826
da Silva, M. K. et al. Computational vaccinology guided design of multi-epitope subunit vaccine against a neglected arbovirus of the Americas. J. Biomol. Struct. Dyn. 41, 3321–3338 (2022).
pubmed: 35285772
doi: 10.1080/07391102.2022.2050301
de Campos, O. D. M., Fulco, U. L., de Oliveira, C. B. S. & Oliveira, J. I. N. SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. J. Evid. Based Med. 13, 255–260 (2020).
pubmed: 33058394
pmcid: 7675315
doi: 10.1111/jebm.12414
Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M. & Barton, G. J. Jalview Version 2—a multiple sequence alignment editor and analysis workbench. Bioinformatics 25(9), 1189–1191 (2009).
pubmed: 19151095
pmcid: 2672624
doi: 10.1093/bioinformatics/btp033
Wang, P. et al. Peptide binding predictions for HLA DR DP and DQ molecules. BMC Bioinform. 11(1), 1–12 (2010).
doi: 10.1186/1471-2105-11-568
Jespersen, M. C., Peters, B., Nielsen, M. & Marcatili, P. BepiPred-2.0: Improving sequence-based B-cell epitope prediction using conformational epitopes. Nucl. Acids Res. 45(W1), W24–W29 (2017).
pubmed: 28472356
pmcid: 5570230
doi: 10.1093/nar/gkx346
Doytchinova, I. A. & Flower, D. R. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform. 8(1), 1–7 (2007).
doi: 10.1186/1471-2105-8-4
Calis, J. J. et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput. Biol. 9(10), e1003266 (2013).
pubmed: 24204222
pmcid: 3808449
doi: 10.1371/journal.pcbi.1003266
Vita, R. et al. The immune epitope database (IEDB) 30. Nucl. Acids Res. 43(D1), D405–D412 (2015).
pubmed: 25300482
doi: 10.1093/nar/gku938
Gupta, S., Kapoor, P., Chaudhary, K., Gautam, A., Kumar, R., Consortium OSDD, et al. In silico approach for predicting toxicity of peptides and proteins. PloS one 8(9), e73957 (2013).
Bui, H.-H. et al. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinform. 7(1), 1–5 (2006).
doi: 10.1186/1471-2105-7-153
Hajighahramani, N. et al. Immunoinformatics analysis and in silico designing of a novel multi-epitope peptide vaccine against Staphylococcus aureus. Infect. Genetics Evol. 48, 83–94 (2017).
doi: 10.1016/j.meegid.2016.12.010
Kadam, A., Santanu, S. & Saudagar, P. Computational design of a potential multi-epitope subunit vaccine using immunoinformatics to fight Ebola virus. Infect. Genetics Evol. 85, 104464 (2020).
doi: 10.1016/j.meegid.2020.104464
Mohan, T., Sharma, C., Bhat, A. A. & Rao, D. Modulation of HIV peptide antigen specific cellular immune response by synthetic α-and β-defensin peptides. Vaccine 31(13), 1707–1716 (2013).
pubmed: 23384751
doi: 10.1016/j.vaccine.2013.01.041
Arai, R., Ueda, H., Kitayama, A., Kamiya, N. & Nagamune, T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng. 14(8), 529–532 (2001).
pubmed: 11579220
doi: 10.1093/protein/14.8.529
Gasteiger, E. et al. Protein identification and analysis tools on the ExPASy server. In The Proteomics Protocols Handbook 571–607 (Humana Press, 2005).
doi: 10.1385/1-59259-890-0:571
Wiederstein, M. & Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucl. Acids Res. 35(suppl_2), W407–W410 (2007).
pubmed: 17517781
pmcid: 1933241
doi: 10.1093/nar/gkm290
Colovos, C. & Yeates, T. O. Verification of protein structures: Patterns of nonbonded atomic interactions. Protein Sci. 2(9), 1511–1519 (1993).
pubmed: 8401235
pmcid: 2142462
doi: 10.1002/pro.5560020916
Eisenberg, D., Lüthy, R. & Bowie, J. U. [20] VERIFY3D: Assessment of protein models with three-dimensional profiles. Methods Enzymol. 277, 396–404 (1997).
pubmed: 9379925
doi: 10.1016/S0076-6879(97)77022-8
Ali, M. et al. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Sci. Rep. 7(1), 1–13 (2017).
doi: 10.1038/s41598-017-09199-w
Pandey, R. K., Sharma, D., Bhatt, T. K., Sundar, S. & Prajapati, V. K. Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: Virtual screening, molecular docking, dynamics and ADMET approach. J. Biomol. Struct. Dyn 33(12), 2541–2553 (2015).
pubmed: 26305585
doi: 10.1080/07391102.2015.1085904
Abbas, A. K., Lichtman, A. H. & Pillai, S. Cellular and Molecular Immunology (Elsevier, 2014).
Pulendran, B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9(10), 741–747 (2009).
pubmed: 19763148
doi: 10.1038/nri2629
Duhovny, D., Nussinov, R., Wolfson, H.J. Efficient unbound docking of rigid molecules. In: International workshop on algorithms in bioinformatics. Springer, 185–200 (2002).
Schneidman-Duhovny, D., Inbar, Y., Nussinov, R. & Wolfson, H. J. PatchDock and SymmDock: Servers for rigid and symmetric docking. Nucl. Acids Res. 33(suppl_2), W363–W367 (2005).
pubmed: 15980490
pmcid: 1160241
doi: 10.1093/nar/gki481
Andrusier, N., Nussinov, R. & Wolfson, H. J. FireDock: Fast interaction refinement in molecular docking. Proteins Struct. Funct. Bioinform. 69(1), 139–159 (2007).
doi: 10.1002/prot.21495
Van Zundert, G. et al. The HADDOCK2.2 web server: User-friendly integrative modeling of biomolecular complexes. J. Mol. Biol. 428(4), 720–725 (2016).
pubmed: 26410586
doi: 10.1016/j.jmb.2015.09.014
Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1, 19–25 (2015).
doi: 10.1016/j.softx.2015.06.001
Andersson, M. P., Jones, M. N., Mikkelsen, K. V., You, F. & Mansouri, S. S. Quantum computing for chemical and biomolecular product design. Curr. Opin. Chem. Eng. 36, 100754 (2022).
doi: 10.1016/j.coche.2021.100754
Kar, R. K. Benefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical systems. Drug Discov. Today 28, 103374 (2022).
pubmed: 36174967
doi: 10.1016/j.drudis.2022.103374
de Sousa, B. G. et al. Molecular modelling and quantum biochemistry computations of a naturally occurring bioremediation enzyme: Alkane hydroxylase from Pseudomonas putida P1. J. Mol. Graph. Modell. 77, 232–239 (2017).
doi: 10.1016/j.jmgm.2017.08.021
Conductance of single microRNAs chains related to the autism spectrum disorder - IOPscience. https://iopscience.iop.org/article/ https://doi.org/10.1209/0295-5075/107/68006 (accessed 18 Jan 2024).
Bezerril, L. M. et al. Charge transport in fibrous/not fibrous α3-helical and (5Q, 7Q) α3 variant peptides. Appl. Phys. Lett. 98(5), 053702 (2011).
doi: 10.1063/1.3551713
De Medeiros, A. S. A. et al. Supramolecular aggregates of oligosaccharides with co-solvents in ternary systems for the solubilizing approach of triamcinolone. Carbohydr. Polym. 151, 1040–1051 (2016).
pubmed: 27474653
doi: 10.1016/j.carbpol.2016.06.044
Vangone, A. & Bonvin, A. M. Contacts-based prediction of binding affinity in protein–protein complexes. elife 4, e07454 (2015).
pubmed: 26193119
pmcid: 4523921
doi: 10.7554/eLife.07454
Mariano, D. et al. BIOINFO–Revista Brasileira de Bioinformática e Biologia Computacional (Alfahelix Publicações, 2021).
doi: 10.51780/978-6-599-275326
Pandey, R. K., Bhatt, T. K. & Prajapati, V. K. Novel immunoinformatics approaches to design multi-epitope subunit vaccine for malaria by investigating anopheles salivary protein. Sci. Rep. 8(1), 1–11 (2018).
doi: 10.1038/s41598-018-19456-1
Goldberg, M. F. et al. Salmonella persist in activated macrophages in T cell-sparse granulomas but are contained by surrounding CXCR3 ligand-positioned Th1 cells. Immunity 49(6), 1090–1102 (2018).
pubmed: 30552021
pmcid: 6301113
doi: 10.1016/j.immuni.2018.10.009
Rapin, N., Lund, O., Bernaschi, M. & Castiglione, F. Computational immunology meets bioinformatics: The use of prediction tools for molecular binding in the simulation of the immune system. PloS One 5(4), e9862 (2010).
pubmed: 20419125
pmcid: 2855701
doi: 10.1371/journal.pone.0009862
Shahab, M., Hayat, C., Sikandar, R., Zheng, G. & Akter, S. In silico designing of a multi-epitope vaccine against Burkholderia pseudomallei: Reverse vaccinology and immunoinformatics. J. Genetic Eng. Biotechnol. 20(1), 1–12 (2022).
doi: 10.1186/s43141-022-00379-4
Akter, S. et al. Immunoinformatics approach to epitope-based vaccine design against the SARS-CoV-2 in Bangladeshi patients. J. Genetic Eng. Biotechnol. 20(1), 1–14 (2022).
doi: 10.1186/s43141-022-00410-8
Vakili, B. et al. A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice. Med. Microbiol. Immunol. 209(1), 69–79 (2020).
pubmed: 31696313
doi: 10.1007/s00430-019-00640-7
Clinical, R. S. & Partnership, T. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet 386(9988), 31–45 (2015).
doi: 10.1016/S0140-6736(15)60721-8
Maciel, M. Jr. et al. Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. Virology 378(1), 105–117 (2008).
pubmed: 18579176
doi: 10.1016/j.virol.2008.04.043
Tottey, S. et al. Plant-produced subunit vaccine candidates against yellow fever induce virus neutralizing antibodies and confer protection against viral challenge in animal models. Am. J. Trop. Med. Hyg. 98(2), 420 (2018).
pubmed: 29231157
doi: 10.4269/ajtmh.16-0293
de Melo, A. B. et al. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and-II binding motifs. PLoS Neglect. Trop. Dis. 7(1), e1938 (2013).
doi: 10.1371/journal.pntd.0001938
Maciel, M. Jr. et al. A DNA vaccine against yellow fever virus: development and evaluation. PLoS Neglect. Trop. Dis. 9(4), e0003693 (2015).
doi: 10.1371/journal.pntd.0003693
Hassan, H. A., Abdelrahman, K. A., Nasr, N. M. & Almofti, Y. A. Identification of novel vaccine candidates against yellow fever virus from the envelope protein: An insilico approach. J. Microbiol. Infect. Dis. 10(01), 31–46 (2020).
doi: 10.5799/jmid.700510
de Tosta, S. F. O. et al. Multi-epitope based vaccine against yellow fever virus applying immunoinformatics approaches. J. Biomol. Struct. Dyn. 39(1), 219–235 (2021).
pubmed: 31854239
doi: 10.1080/07391102.2019.1707120
Dar, H. et al. Prediction of promiscuous T-cell epitopes in the Zika virus polyprotein: An in silico approach. Asian Pac. J. Trop. Med. 9(9), 844–850 (2016).
pubmed: 27633296
doi: 10.1016/j.apjtm.2016.07.004
McNeil, M. M. & DeStefano, F. Vaccine-associated hypersensitivity. J. Allergy Clin. Immunol. 141(2), 463–472 (2018).
pubmed: 29413255
pmcid: 6602527
doi: 10.1016/j.jaci.2017.12.971
Chen, X., Zaro, J. & Shen, W.-C. Fusion protein linkers: effects on production, bioactivity, and pharmacokinetics. In Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges 57–73 (Willey, 2013).
doi: 10.1002/9781118354599.ch4
Patronov, A. & Doytchinova, I. T-cell epitope vaccine design by immunoinformatics. Open Biol. 3(1), 120139 (2013).
pubmed: 23303307
pmcid: 3603454
doi: 10.1098/rsob.120139
Patel, S. M., Koringa, P. G., Reddy, B. B., Nathani, N. M. & Joshi, C. G. In silico analysis of consequences of non-synonymous SNPs of Slc11a2 gene in Indian bovines. Genomics Data 5, 72–79 (2015).
pubmed: 26484229
pmcid: 4583633
doi: 10.1016/j.gdata.2015.05.015
Chen, R. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol. Adv. 30(5), 1102–1107 (2012).
pubmed: 21968145
doi: 10.1016/j.biotechadv.2011.09.013
Baneyx, F. Recombinant protein expression in Escherichia coli. Curr. Opin. Biotechnol. 10(5), 411–421 (1999).
pubmed: 10508629
doi: 10.1016/S0958-1669(99)00003-8
Six, A., Bellier, B., Thomas-Vaslin, V. & Klatzmann, D. Systems biology in vaccine design. Microb. Biotechnol. 5(2), 295–304 (2012).
pubmed: 22189033
pmcid: 3815789
doi: 10.1111/j.1751-7915.2011.00321.x
Spellberg, B. & Edwards, J. E. Jr. Type 1/Type 2 immunity in infectious diseases. Clin. Infect. Dis. 32(1), 76–102 (2001).
pubmed: 11118387
doi: 10.1086/317537
Lodoen, M. B. & Lanier, L. L. Natural killer cells as an initial defense against pathogens. Curr. Opin. Immunol. 18(4), 391–398 (2006).
pubmed: 16765573
pmcid: 7127478
doi: 10.1016/j.coi.2006.05.002
Marquardt, N. et al. The human NK cell response to yellow fever virus 17D is primarily governed by NK cell differentiation independently of NK cell education. J. Immunol. 195(7), 3262–3272 (2015).
pubmed: 26283480
doi: 10.4049/jimmunol.1401811
Azevedo, A.C.C., Pereira, C.C., do Antonelli, L.R.V., Fonseca, C.T., Carvalho, A.T., Rezende, G.V., et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. (2016).